在瘤血液病患者的多药和药物相互作用的瘤血液连接组网络基表型化
Sabina-Oana Vasii1,2, Daiana Colibășanu1,2,3, Florina-Diana Goldiș1,2
1Center for Drug Data Analysis, Cheminformatics, and the Internet of Medical Things, Victor Babeş University of Medicine and Pharmacy Timişoara, 300041 Timişoara, Romania.
Pharmaceutics
|February 27, 2026
概括
瘤-瘤连接组根据临床表型对血液瘤患者进行了组织,根据并发症和药物使用,揭示了不同的患者组. 该网络有助于开发有针对性的支持性护理和风险模型,以改善患者的治疗结果.
科学领域:
- 计算生物学和生物信息学
- 瘤学和血液学研究研究.
- 卫生信息学和数据科学
背景情况:
- 多药和药物相互作用 (DDI) 是血液瘤学中的重大挑战.
- 患者护理的复杂性因伴随疾病和治疗强度而异.
研究的目的:
- 引入Onco-Hem连接组 (OHC),一个患者相似性网络 (PSN).
- 根据具有潜在临床实用性的探索性表型对血液瘤学住院患者进行组织.
- 为了改善临床决策,确定不同的患者子组.
主要方法:
- 对2023年单中心队列 (298名患者,1158例医院发作) 的回顾性分析.
- 使用标准化特征向量 (人口统计,并发症,多药学得分,DDI,诊断,药物暴露) 构建PSN.
- 通过基于模块化的聚类和按药物,诊断和化疗方案进行分析来进行社区检测.
主要成果:
- 该OHC包括295个节点和4179个边缘,产生了五个不同的社区.
- 社区在并发症负担 (查尔森,埃利克沙瑟,年龄) 上有显著差异,但在停留时间或发作方面没有显著差异.
- 药物丰富和社区内的主要诊断支持了不同的临床表型,其稳定性得到了ARI和NMI评分的证实.
结论:
- 瘤-血液连接组为血液瘤学提供可解释的,表型级的洞察力.
- 调查结果可以为支持性护理包,DDI意识的处方和管理计划提供信息.
- 在血液瘤学中,OHC 作为开发表型特异性风险模型的基础.
相关概念视频
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
63
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
63
Pharmacogenomics: Identification of New Drug Targets
53
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
53
Pharmacogenetics and Pharmacogenomics: Overview
74
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
74
Therapeutic Drug Monitoring: Affecting Factors
288
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
288
Drug toxicity: Drug–Drug Interaction
110
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
110
Pharmacogenetics of Drug Metabolism: Overview
68
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
68


